The CLH proposals for the eight anticoagulants have been submitted by eight different Member State competent authorities and concern the following substances: chlorophacinone, difenacoum, warfarin, difethialone, bromadiolone, coumatetralyl, brodifacoum and flocoumafen. These anticoagulants are all rodenticides and can also potentially be fatal to humans. They are being launched for public consultation at the same time as they act in a similar manner and are expected to have similar toxicological properties.
Chlorophacinone, difenacoum, warfarin and flocoumafen already have a harmonised classification and labelling listed in Part 3 of Annex VI to the CLP Regulation and revisions to the current classification for both health and environment hazards are being proposed. The other four rodenticides difethialone, bromadiolone, coumatetralyl and brodifacoum do not have a current Annex VI entry and the proposals also cover health and environmental hazards. Most of these substances have specific concentration limits related to one or more hazard classes.
CLH proposals on 475-glass special purpose fibres and E-glass special purpose fibres have been submitted by France. Both fibres are currently associated to fibres with an existing harmonised classification and labelling listed in Annex VI to the CLP Regulation. However, the dossier submitter is proposing new Annex VI entries with specific composition information, changes to notes and carcinogenicity classification.
The industrial chemical phenol, dodecyl-, branched has been submitted by an industrial company. The substance does not have an Annex VI entry and the proposal focuses only on reproductive toxicity. Another CLH proposal for the same substance by a different dossier submitter was submitted earlier to ECHA for which a public consultation ended on 1 February 2013. The category proposed for reproductive toxicity in this current proposal is more severe than in the previous submission.
The CLH proposals and the dedicated webform for posting comments are available on the ECHA website. The comments received during the public consultation will be regularly published on the ECHA website during the 45-day consultation phase.